Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23091756 | 0.78 | USP2 (0.43) | SMN1; SMN2CYP2D6MEN1KMT2ATAAR1 | |
| SCHEMBL23886286 | 0.74 | CYP2D6 (0.53) | CYP2D6TAAR1 | |
| SCHEMBL2282246 | 0.73 | CYP2D6 (0.45) | SMN1; SMN2CYP2D6MEN1KMT2AGRIN2B | |
| Acetic Acid SCHEMBL11160294 | 0.72 | SMN1; SMN2 (0.53) | HPGDSMN1; SMN2CYP2D6GAAMEN1 | |
| Trifluoroacetic Acid SCHEMBL5076872 | 0.72 | TAAR1 (0.70) | TAAR1 | |
| Trifluoroacetic Acid SCHEMBL5076869 | 0.72 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1KMT2ATAAR1CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL27196363 | 0.72 | TACR1 (0.44) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| Trifluoroacetic Acid SCHEMBL27196373 | 0.72 | TACR1 (0.44) | MEN1KMT2ACYP2C9CYP2C19MAPK14 | |
| SCHEMBL3908258 | 0.71 | MEN1 (0.38) | HPGDSMN1; SMN2CYP2D6GAAMEN1 | |
| SCHEMBL2165486 | 0.70 | CYP2D6 (0.47) | HPGDCYP2D6GAATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799639-B1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-7538128-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7524844-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-11 | — | — | US | disclosed |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-04 | — | — | US | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACETUCALS, S.A. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | DPP4, DPP3, DPP7 | HPGD 2751/4885SMN1; SMN2 4277/4885CYP2D6 332/4885 |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | HPGD 3460/4885SMN1; SMN2 4297/4885CYP2D6 647/4885 |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | HPGD 3460/4885SMN1; SMN2 4297/4885CYP2D6 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.